• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

C60 for MS and diabetes Type 1

c60 diabetes

  • Please log in to reply
7 replies to this topic

#1 aribadabar

  • Guest
  • 860 posts
  • 267
  • Location:Canada
  • NO

Posted 03 May 2015 - 09:18 PM


Hello guys,

 

 

I have two close friends who have been diagnosed with MS (2 yrs ago, she is 48 now) and diabetes type 1 (since age 3, he is 50 now).

The MS patient has relatively mild symptoms of numbness and urinary urgency issues while the diabetic is now suffering from complications of severe (I think) diabetic neuropathy - significant loss of taste (most of the foods taste bland to horrible) and balance (he reports that if he closes his eyes and is standing he would fall), constant numbness in legs, wildly oscillating blood glucose levels.

 

Do you think c60oo would provide some relief for their conditions?

 

Many thanks!


Edited by aribadabar, 03 May 2015 - 10:09 PM.

  • like x 1

#2 Walter Derzko

  • Guest
  • 137 posts
  • -2
  • Location:Toronto

Posted 03 May 2015 - 09:53 PM

C60 and Type 1 diabetes

C60 should help control inflammation -helps for sure in Type 2 diabetes. Type 2 diabetes is also a deficiency of essential and trace minerals in the diet, especially chromium and vanadium and a host of other co-factors. May help with Type 1 diabetes -not sure. Check out PUBMED and my talk last week Aging Gracefully without Chronic Human Diseases https://www.academia...ses_v4_UPDATED_

Edited by Walter Derzko, 03 May 2015 - 10:00 PM.


Click HERE to rent this advertising spot for C60 HEALTH to support Longecity (this will replace the google ad above).

#3 Walter Derzko

  • Guest
  • 137 posts
  • -2
  • Location:Toronto

Posted 03 May 2015 - 10:09 PM

C60 and MS

A neighbour of mine, who is over 80 years old and has MS for some time now, has been drinking Carbon 60 hydrated fullerene water, 50 mls or 3 tablespoons per day at 0.0002 mg per 100ml. After one month she says it is helping to control her MS symptoms. MS has been linked to oxidative stress and lipid peroxidation. (see below) I suspect C60-oo should help too.

###

Curr Top Med Chem. 2014;14(22):2590-9.
Novel targets in multiple sclerosis: to oxidative stress and beyond.
Chiurchiù V1.
Author information
• 1European Center for Brain Research (CERC), I.R.C.C.S. Santa Lucia Foundation, via del Fosso di Fiorano 64, 00143, Rome, Italy. v.chiurchiu@hsantalucia.it.
Abstract
Despite multiple sclerosis (MS) represents one of the most fascinating mystery of modern medicine due to its unknown etiology and the incomplete knowledge of a clear mechanism of pathogenesis, progress against this disease has made giant leaps. Current management of MS takes advantage of many disease- modifying therapeutics of anti-inflammatory and immunomodulatory nature, whose primary aims are halting immune responses during attacks, preventing new attacks and avoiding disability. In this review, a synopsis on effective therapies targeting both immune-mediated responses and neurodegenerative processes is appointed. Oxidative stress has been also implicated in both the inflammatory and neurodegenerative pathological mechanisms underlying MS. The role of redox metabolism in MS is thus also reported, with particular focus on the latest improvements in the identification of oxidative stress as a potential new therapeutic target.
http://www.ncbi.nlm....pubmed/25478879

###

Eur Neurol. 2014 Sep 30;72(3-4):249-254. [Epub ahead of print]
Oxidative Stress Induced by Lipid Peroxidation Is Related with Inflammation of Demyelination and Neurodegeneration in Multiple Sclerosis.
Wang P1, Xie K, Wang C, Bi J.
Author information
• 1Department of Neurology, The Affiliated Hospital of Shandong University, Jinan, Shandong, PR China.
Abstract
Background: Multiple sclerosis (MS) is a chronic autoimmune demyelination disorder of the central nervous system (CNS) and its etiology remains unknown. The inflammatory environment in demyelinating lesions leads to the generation of oxygen- and nitrogen-free radicals as well as proinflammatory cytokines, which contribute to the development and progression of multiple sclerosis. Inflammation can lead to oxidative stress and vice versa. Thus, oxidative stress is involved in the inflammation leading demyelination and neurodegeneration in the pathogenesis of multiple sclerosis.
Summary: The present study aims to determine two biochemical markers of oxidative stress: TAC and MDA and to show their correlations whether oxidative stress reaction occurs in the demyelination through analyzing samples including peripheral blood and cerebrospinal fluid (CSF) from patients with relapsing-remitting MS (RR-MS). Totally, there were 20 patients in the control groups made from individuals with normal pressure hydrocephalus. Thirty MS patients diagnosed with McDonald diagnostic criteria (2010) treated with methylprednisolone were included in this study. Data were stratified by the degree of severity in order to clarify the role of oxidative stress in the mechanisms of MS and to assess its potential as a biomarker. Thirty clinically definite RRMS patients were enrolled in this study. Levels of MDA, GSH, total antioxidant capacity TAC, GSH-Px and ROS, were determined in serum of the control group and RRMS patients in 7 days before MP (methylprednisolone) treatment and one month after MP treatment. Statistical analysis was performed with one-way analysis of variance (ANOVA), followed by LSD's post hoc tests.
Key Messages: Oxidative stress precedes the inflammatory response in the multiple sclerosis patients. And methylprednisolone treatment can decrease brain antioxidant enzymes to reduce the neuroinflammatory attack. © 2014 S. Karger AG, Basel.

###

Lancet Neurol. 2015 Feb;14(2):183-193. doi: 10.1016/S1474-4422(14)70256-X.
Pathological mechanisms in progressive multiple sclerosis.
Mahad DH1, Trapp BD2, Lassmann H3.
Author information
• 1Centre for Neuroregeneration, University of Edinburgh, Edinburgh, UK.
• 2Department of Neurosciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
• 3Center for Brain Research, Medical University of Vienna, Austria. Electronic address: hans.lassmann@meduniwien.ac.at.
Abstract
A better understanding of the pathological mechanisms that drive neurodegeneration in individuals with multiple sclerosis is needed to develop therapies that will effectively treat patients in the primary and secondary progressive stages of the disease. We propose that the inflammatory demyelinating disease process in early multiple sclerosis triggers a cascade of events that lead to neurodegeneration and are amplified by pathogenic mechanisms related to brain ageing and accumulated disease burden. Key elements driving neurodegeneration include microglia activation, chronic oxidative injury, accumulation of mitochondrial damage in axons, and age-related iron accumulation in the human brain. Altered mitochondrial function in axons might be of particular importance. This process leads to chronic cell stress and imbalance of ionic homoeostasis, resulting in axonal and neuronal death. The evidence suggests that treatment of progressive multiple sclerosis should be based on a combination of anti-inflammatory, regenerative, and neuroprotective strategies.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Edited by Walter Derzko, 03 May 2015 - 10:10 PM.


#4 Daniel Cooper

  • Member, Moderator
  • 2,649 posts
  • 633
  • Location:USA

Posted 04 May 2015 - 02:24 AM

C60 and Type 1 diabetes

C60 should help control inflammation -helps for sure in Type 2 diabetes. Type 2 diabetes is also a deficiency of essential and trace minerals in the diet, especially chromium and vanadium and a host of other co-factors. May help with Type 1 diabetes -not sure. Check out PUBMED and my talk last week Aging Gracefully without Chronic Human Diseases https://www.academia...ses_v4_UPDATED_

 

Walter - do you have any evidence that type 2 diabetes is linked to a deficiency of essential trace minerals, particularly chromium and vanadium? 


  • Off-Topic x 1
  • like x 1

#5 Walter Derzko

  • Guest
  • 137 posts
  • -2
  • Location:Toronto

Posted 04 May 2015 - 03:46 AM

Lots. check PUBMED

Adv Biomed Res. 2014 Nov 29;3:235. doi: 10.4103/2277-9175.145737. eCollection 2014.

Chromium level in prediction of diabetes in pre-diabetic patients.

Rafiei R1, Habyby Z1, Fouladi L1, Najafi S2, Asgary S3, Torabi Z4.



Author information






Abstract

BACKGROUND:

Chromium supplementations (Cr) have been shown to exert beneficial effects in the management of type-2 diabetes. Prevalence of Cr deficiency in pre-diabetic patients is not well-understood, therefore, the aim of this study was to evaluate the extent of this prevalence.

MATERIALS AND METHODS:

In this cross-sectional descriptive study, 132 pre-diabetic patients were recruited. The participants were randomly selected from those who referred to the Shariati Hospital in Isfahan, Iran. Blood samples are collected for measurement of Cr, insulin, fasting blood sugar (FBS), and two-hour post-load plasma glucose. The body mass index (BMI) was calculated. Determination of Cr was carried out by atomic absorption spectrometry.

RESULTS:

Thirty-four (31.5%) patients had Cr deficiency and 74 (68.5%) patients had normal Cr. There was no significant difference between sex, age groups (<50 years and ≥50 years) and between patients with and without a family history of diabetes in both the groups. No significant differences in age, BMI, FBS or insulin were observed between two groups. In the group with a normal level of Cr, there was a significant reversed correlation between the Cr level and age, but no significant correlation existed between the Cr level and other factors in both groups.

CONCLUSION:

The levels of Cr deficiency are relatively common in patients with pre-diabetes, and it is necessary to screen patients with diabetes and pre-diabetes according to the American Diabetes Association guidelines, with regard to the Cr level and action should be taken to eliminate the Cr deficiency in these patients.


KEYWORDS:

Chromium; insulin; pre-diabetic

Edited by Walter Derzko, 04 May 2015 - 03:56 AM.

  • Off-Topic x 1

#6 Walter Derzko

  • Guest
  • 137 posts
  • -2
  • Location:Toronto

Posted 04 May 2015 - 03:52 AM

Chemosphere. 2015 Mar 28;132:101-107. doi: 10.1016/j.chemosphere.2015.02.052. [Epub ahead of print]

Association of trace elements with lipid profiles and glycaemic control in patients with type 1 diabetes mellitus in northern Sardinia, Italy: An observational study.

Peruzzu A1, Solinas G2, Asara Y3, Forte G4, Bocca B5, Tolu F6, Malaguarnera L7, Montella A8, Madeddu R9.

Author information

Abstract

Sardinia is an Italian region with a high incidence of type 1 diabetes mellitus. This study aimed to determine the associations of trace elements with lipid profiles and glycaemic control in patients with T1DM. A total of 192 patients with T1DM who attended the Unit of Diabetology and Metabolic Diseases in Sassari, Italy, were enrolled. Trace elements zinc, copper, selenium, chromium, and iron were measured in whole blood by sector field inductively coupled plasma mass spectrometry. The correlations between metabolic variables and the levels of trace elements were determined. Zinc was positively correlated with total cholesterol (P=0.023), low-density lipoprotein (P=0.0015), and triglycerides (P=0.027). Iron as significantly correlated with TC (P=0.0189), LDL (P=0.0121), and high-density lipoprotein (HDL) (P=0.0466). In males, Cr was positively correlated with HDL (P=0.0079) and Se, in females was correlated with TG (P=0.0113). The mean fasting plasma glucose was166.2mgdL-1. Chromium was correlated with fasting plasma glucose (P=0.0149), particularly in males (P=0.0038). Overall, 63.5% of the patients had moderate HbA1c (7-9%). Copper was significantly correlated with HbA1c% in males (P=0.0155). In conclusion, the results of this study indicate that trace elements show different associations with lipid levels and glycaemic control in T1DM. Zinc, Fe, and Se were associated with lipid levels whereas Cu and Cr were associated with HbA1c%.

Copyright © 2015 Elsevier Ltd. All rights reserved.


KEYWORDS:

Glycaemic control; Lipid profile; Trace elements; Type 1 diabetes mellitus (T1DM)

Edited by Walter Derzko, 04 May 2015 - 03:52 AM.

  • Off-Topic x 1

#7 Daniel Cooper

  • Member, Moderator
  • 2,649 posts
  • 633
  • Location:USA

Posted 06 May 2015 - 03:51 AM

Lots. check PUBMED

Adv Biomed Res. 2014 Nov 29;3:235. doi: 10.4103/2277-9175.145737. eCollection 2014.

Chromium level in prediction of diabetes in pre-diabetic patients.

Rafiei R1, Habyby Z1, Fouladi L1, Najafi S2, Asgary S3, Torabi Z4.



Author information






Abstract

BACKGROUND:

Chromium supplementations (Cr) have been shown to exert beneficial effects in the management of type-2 diabetes. Prevalence of Cr deficiency in pre-diabetic patients is not well-understood, therefore, the aim of this study was to evaluate the extent of this prevalence.

MATERIALS AND METHODS:

In this cross-sectional descriptive study, 132 pre-diabetic patients were recruited. The participants were randomly selected from those who referred to the Shariati Hospital in Isfahan, Iran. Blood samples are collected for measurement of Cr, insulin, fasting blood sugar (FBS), and two-hour post-load plasma glucose. The body mass index (BMI) was calculated. Determination of Cr was carried out by atomic absorption spectrometry.

RESULTS:

Thirty-four (31.5%) patients had Cr deficiency and 74 (68.5%) patients had normal Cr. There was no significant difference between sex, age groups (<50 years and ≥50 years) and between patients with and without a family history of diabetes in both the groups. No significant differences in age, BMI, FBS or insulin were observed between two groups. In the group with a normal level of Cr, there was a significant reversed correlation between the Cr level and age, but no significant correlation existed between the Cr level and other factors in both groups.

CONCLUSION:

The levels of Cr deficiency are relatively common in patients with pre-diabetes, and it is necessary to screen patients with diabetes and pre-diabetes according to the American Diabetes Association guidelines, with regard to the Cr level and action should be taken to eliminate the Cr deficiency in these patients.


KEYWORDS:

Chromium; insulin; pre-diabetic

 

 

At best that study proves that low chromium and type 2 diabetes are epiphenomena, it does not prove that type 2 diabetes is caused by low chromium levels.  For that you'd have to administer chromium supplements to diabetic patients and demonstrate that they get better, which this study did not do.  For all we know, type 2 diabetes causes malabsorption of chromium.

 


 


  • Off-Topic x 1
  • Disagree x 1
  • Agree x 1

#8 Walter Derzko

  • Guest
  • 137 posts
  • -2
  • Location:Toronto

Posted 06 May 2015 - 04:35 AM

Lost of research on PUBMED, keep looking
11,589 paper
http://www.ncbi.nlm.... micronutrients


Diabetes, essential and trace minerals, cofactors, caloric restriction and C60

###

Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol

E. L. Lim & K. G. Hollingsworth & B. S. Aribisala & M. J. Chen & J. C. Mathers & R. Taylor
Received: 22 March 2011 /Accepted: 5 May 2011 # The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract
Aims/hypothesis Type 2 diabetes is regarded as inevitably progressive, with irreversible beta cell failure. The hypothesis was tested that both beta cell failure and insulin resistance can be reversed by dietary restriction of energy intake.

Methods
Eleven people with type 2 diabetes (49.5± 2.5 years, BMI 33.6±1.2 kg/m2, nine male and two female) were studied before and after 1, 4 and 8 weeks of a 2.5 MJ (600 kcal)/day diet. Basal hepatic glucose output, hepatic and peripheral insulin sensitivity and beta cell function were measured. Pancreas and liver triacylglycerol content was measured using three-point Dixon magnetic resonance imaging. An age-, sex- and weight-matched group of eight non-diabetic participants was studied. Results After 1 week of restricted energy intake, fasting plasma glucose normalised in the diabetic group (from 9.2± 0.4 to 5.9±0.4 mmol/l; p=0.003). Insulin suppression of hepatic glucose output improved from 43±4% to 74±5% (p= 0.003 vs baseline; controls 68±5%). Hepatic triacylglycerol content fell from 12.8±2.4% in the diabetic group to 2.9± 0.2% by week 8 (p=0.003). The first-phase insulin response increased during the study period (0.19±0.02 to 0.46± 0.07 nmol min−1 m−2; p<0.001) and approached control values (0.62±0.15 nmol min−1 m−2; p=0.42). Maximal insulin response became supranormal at 8 weeks (1.37± 0.27 vs controls 1.15±0.18 nmol min−1 m−2). Pancreatic triacylglycerol decreased from 8.0±1.6% to 6.2±1.1% (p=0.03).

Conclusions/interpretation
Normalisation of both beta cell function and hepatic insulin sensitivity in type 2 diabetes was achieved by dietary energy restriction alone. This was associated with decreased pancreatic and liver triacylglycerol stores. The abnormalities underlying type 2 diabetes are reversible by reducing dietary energy intake.

Keywords Insulin secretion. Liver fat. Low energy diet. Pancreatic fat. Type 2 diabetes



###

Treat Endocrinol. 2004;3(1):41-52.
The role of antioxidant micronutrients in the prevention of diabetic complications.
Bonnefont-Rousselot D1.
Author information
• 1Laboratoire de Biochimie Métabolique et Clinique (EA 3617), Faculté de Pharmacie, Paris, France. dominique.rousselot@psl.ap-hop-paris.fr
Abstract
Diabetes mellitus is associated with an increased production of reactive oxygen species and a reduction in antioxidant defenses. This leads to oxidative stress, which is partly responsible for diabetic complications. Tight glycemic control is the most effective way of preventing or decreasing these complications. Nevertheless, antioxidant micronutrients can be proposed as adjunctive therapy in patients with diabetes. Indeed, some minerals and vitamins are able to indirectly participate in the reduction of oxidative stress in diabetic patients by improving glycemic control and/or are able to exert antioxidant activity. This article reviews the use of minerals (vanadium, chromium, magnesium, zinc, selenium, copper) and vitamins or cofactors (tocopherol [vitamin E], ascorbic acid [vitamin C], ubidecarenone [ubiquinone; coenzyme Q], nicotinamide, riboflavin, thioctic acid [lipoic acid], flavonoids) in diabetes, with a particular focus on the prevention of diabetic complications. Results show that dietary supplementation with micronutrients may be a complement to classical therapies for preventing and treating diabetic complications. Supplementation is expected to be more effective when a deficiency in these micronutrients exists. Nevertheless, many clinical studies have reported beneficial effects in individuals without deficiencies, although several of these studies were short term and had small sample sizes. However, a randomized, double-blind, placebo-controlled, multicenter trial showed that thioctic acid at an oral dosage of 800 mg/day for 4 months significantly improved cardiac autonomic neuropathy in type 2 diabetic patients. Above all, individuals with diabetes should be educated about the importance of consuming adequate amounts of vitamins and minerals from natural food sources, within the constraints of recommended sugar and carbohydrate intake.

###

Oxidative stress, micronutrients, diabetes mellitus and its complications
The Journal of The Royal Society for the Promotion of Health; March 2002, 122 (1), pp. 28-34
ECOpara
Emmanuel C Opara, MSc, PhD, Associate Research Professor, Division of Experimental Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA Email: opara001@mc.duke.edu Corresponding author: Emmanuel C Opara, Box 3065, Duke University Medical Center (as above) Received 18 October 2000, revised and accepted 2February 2001
Key words Antioxidants; diabetes mellitus (DM); diabetic complications; oxidative stress

Abstract
Oxidative stress is defined as excessive production of reactive oxygen species (ROS) in the presence of diminished antioxidant substances. It has been shown that oxidative stress has an adverse effect on glucose metabolism. Development of the disabling chronic complications of diabetes mellitus (DM) has also been attributed to oxidative stress. The bodys defence against oxidative stress is accomplished by interconnecting systems of antioxidant micronutrients (vitamins and minerals) and enzymes. While the vitamins act as donors and acceptors of ROS, minerals regulate activity of the enzymes. This review article is focused on the preventive and therapeutic roles of these antioxidant micronutrients in DM. Although there is scarcity of data from controlled studies, anecdotal reports indicate that the use of certain antioxidant vitamin and mineral supplements may be beneficial as an adjunct therapy in the management of DM and its complications. In particular, it has been reported that high doses of single micronutrient antioxidant supplements, such as vitamin E, may be beneficial to patients suffering from this disease. However, micronutrient antioxidants interact with each other in a biochemical chain of defence against free radicals, and the use of high doses of a single antioxidant poses potential risks because it could perturb the antioxidant-prooxidant balance. It has, therefore, been recommended that high doses of micronutrient antioxidant vitamins should be administered in combination rather than as single supplements. There are a growing number of preparations containing mixtures of antioxidant vitamins and/or trace elements. A particularly impressive supplement is a new formula called Akesis, which is a mixture of antioxidant vitamins and antidiabetic trace elements, adequately balanced with other vitamins and minerals that enhance metabolic processes.

###

Toxicology. 2011 Apr 11;282(3):69-81. doi: 10.1016/j.tox.2010.12.003. Epub 2010 Dec 14.

Protective effects of nanostructures of hydrated C(60) fullerene on reproductive function in streptozotocin-diabetic male rats.

Bal R1, Türk G, Tuzcu M, Yilmaz O, Ozercan I, Kuloglu T, Gür S, Nedzvetsky VS, Tykhomyrov AA, Andrievsky GV, Baydas G, Naziroglu M.



Author information


Abstract

Diabetes mellitus is a well-recognized cause of male sexual dysfunction and impairments of male fertility. Streptozotocin (STZ) is used for medical treatment of neoplastic islet β-cells of pancreas and producing of animal model of diabetes mellitus type 1 that is characterized by suppression of reproductive activity due to the hyperglycaemia-induced oxidative stress and histopathological alterations in testes. Seeking for the agents that could alleviate diabetes-induced damage to reproductive system is yet the important area of inquiry. The present study was designed to evaluate whether hydrated C(60) fullerene (C(60)HyFn), which is known to be powerful bioantioxidant, eliminate testicular dysfunction induced by STZ-diabetes in rats. Wistar strain male albino rats were divided into four groups of six animals each: (1) control group, (2) C(60)HyFn-treated nondiabetic group, (3) STZ-diabetic group and (4) C(60)HyFn-treated diabetic group. Once hyperglycaemia was induced by STZ, rats in the second and fourth groups were treated with C(60)HyFn (in the form of drinking water) at the dose of 4μg/kg daily for 5 weeks. In diabetic rats, relative weights of right cauda epididymis, seminal vesicles, prostate, sperm motility and epididymal sperm concentration were significantly less than those of control group, but which were restored in the fourth group treated with C(60)HyFn (p<0.001). In hematoxylin and eosin staining, marked histopathological changes including degeneration, desquamation, disorganisation and reduction in germinal cells, interstitial oedema and congestion were evident in the testis of diabetic rats, but C(60)HyFn treatment resulted in recovery of histopathological changes and an increase in Johnsen's testicular score significantly (p<0.001). C(60)HyFn treatment restores the increased apoptosis induced by STZ-diabetes. In diabetic rats, levels of serum testosterone, testicular reduced glutathione (GSH) and alpha-tocopherol were significantly reduced and testicular lipid peroxidation level was increased (p<0.001). Nevertheless, treatment of diabetic rats with C(60)HyFn resulted in significant corrective effects on these parameters towards the control levels. C(60)HyFn, applied alone, did not exert any toxic effects in testicular tissues. Furthermore, C(60)HyFn treatment in diabetic and nondiabetic rats resulted in considerable elevations of some important polyunsaturated fatty acids. In conclusion, we have presented for the first time substantial evidence that administration of C(60)HyFn significantly reduces diabetes-induced oxidative stress and associated complications such as testicular dysfunction and spermatogenic disruption.

Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Edited by Walter Derzko, 06 May 2015 - 04:45 AM.

  • Off-Topic x 1





Also tagged with one or more of these keywords: c60, diabetes

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users